Amantin

Amantin

escitalopram

Manufacturer:

Akums Drug

Distributor:

Bell-Kenz Pharma

Marketer:

Ambica
Concise Prescribing Info
Contents
Escitalopram oxalate
Indications/Uses
Depression, panic disorder w/ or w/o agoraphobia, generalized anxiety disorder, social anxiety disorder, & obsessive-compulsive disorder.
Dosage/Direction for Use
Depression 10 mg once daily. Increased after at least a wk to max of 20 mg once daily if necessary. Panic disorder w/ or w/o agoraphobia Initially 5 mg once daily. Increased after a wk to 10 mg once daily; further increases up to max of 20 mg daily. Elderly Initially half the recommended dose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use w/ MAOIs. Childn.
Special Precautions
Discontinue in any patient entering a manic phase; who develops seizures. Increased anxiety symptoms in patients w/ panic disorders. Avoid in patients w/ unstable epilepsy. Closely monitor patients w/ controlled epilepsy. May alter glycaemic control in patients w/ DM. Suicide; haemorrhage. Avoid abrupt w/drawal. Patients w/ hepatic impairment or those who are poor metabolisers of CYP2C19. Not to be used during pregnancy. Not recommended during lactation. Not recommended in childn & adolescents <18 yr.
Adverse Reactions
Nausea, insomnia, somnolence, increased sweating, diarrhea, constipation, dizziness, fatigue, decreased appetite, sinusitis, decreased libido, pyrexia, yawning. Ejaculation disorder, impotence, abnormal orgasm (female).
Drug Interactions
May cause serotonin syndrome w/ MAOIs. May lead to enhancement of serotonin associated effects eg, serotonin syndrome w/ other serotogenic medicines (eg, tramadol, sumatriptan) as well as other antidepressants w/ serotonergic properties.
MIMS Class
Antidepressants
ATC Classification
N06AB10 - escitalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.
Presentation/Packing
Form
Amantin FC tab 10 mg
Packing/Price
10's;30's;50's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in